Immunosuppressive therapy around the time of elective surgery in patients suffering from rheumatic diseases;Immunsuppressive therapie bei patienten mit rheumatischen erkrankungen im vorfeld elektiver operationen

Arzneimitteltherapie

Volumn 26, Issue 9, 2008, Pages 332-336

  Härle, Peter ^a   Fleck, Martin ^a,b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b Asklepios Klinikum Bad Abbach   (Germany)

Author keywords

DMARD; Infection; Rheumatic diseases; Surgery; Wound healing

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; COLESTYRAMINE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LANTAREL; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG MECHANISM; ELECTIVE SURGERY; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; MONOTHERAPY; PERIOPERATIVE PERIOD; PSORIASIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPSIS; WOUND INFECTION;

EID: 77953440063     PISSN: 07236913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-9.
2. van Burik JA, Carter SL, Freifeld AG, et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T-cell depleted unrelated bone marrow: analysis of infectious complications in patients treated with T-cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant 2007;13:1487-98.
3. Gluck T, Kiefmann B, Grohmann M, et al. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol 2005;32:1473-80.
4. Doran MF, Crowson CS, Pond GR, O'Fallon WM, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
5. Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, et al. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 1995;24:411-21.
6. den Broeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007;34:689-95.
7. Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007;275:71-8.
8. Badsha H, Edwards CJ. Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003;32:370-7.
9. Anstead GM. Steroids, retinoids, and wound healing. Adv Wound Care 1998;11:277-85.
10. Seitz M, Valbracht J, Quach J, Lotz M. Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic THP-1 cells through distinct transcriptional and posttranslational mechanisms. J Clin Immunol 2003;23:477-84.
11. Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001;60:214-7.
12. Bibbo C, Anderson RB, Davis WH, Norton J. The influence of rheumatoid chemotherapy, age, and presence of rheumatoid nodules on postoperative complications in rheumatoid foot and ankle surgery: analysis of 725 procedures in 104 patients [corrected]. Foot Ankle Int 2003;24:40-4.
13. Ash G, Baker R, Rajapakse C, Swinson DR. Study of sulphamethoxazole in rheumatoid arthritis. Br J Rheumatol 1986;25:285-7.
14. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951;221:176-82.
15. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A meta-analysis of published clinical trials. Arthritis Rheum 1992;35:1117-25.
16. Cronstein BN, Naime D, Ostad E. The antiinflammatory effects of methotrexate are mediated by adenosine. Adv Exp Med Biol 1994;370:411-6.
17. Davis JP, Cain GA, Pitts WJ, Magolda RL, et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996:35:1270-3.
18. Kraan MC, Smeets TJ, van Loon MJ, et al. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis 2004;63:1056-61.
19. Xu X, Williams JW, Bremer EG, Finnegan A, et al. Inhibition of protein tyrosine phosphorylation in T-cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995;270:12398-403.
20. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000;165:5962-9.
21. Delank KS, Hansen T, Eysel P, Eckardt A. [Infections of the musculoskeletal system with chronic polyarthritis during a combination therapy with Methotrexate and Leflunomide]. Z Orthop Ihre Grenzgeb 2002;140:555-60.
22. Fuerst M, Mohl H, Baumgartel K, Ruther W. Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Rheumatol Int 2006;26:1138-42.
23. Bibbo C, Goldberg JW. Infectious and healing complications after elec tive orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004;25:331-5.
24. Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006;55:333-7.
25. Ruyssen-Witrand A, Gossec L, Salliot C, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 2007;25:430-6.
26. Bridges SL Jr., Lopez-Mendez A, Han KH, Tracy IC, et al. Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis? J Rheumatol 1991;18:984-8.
27. Perhala RS, Wilke WS, Clough JD, Segal AM. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum 1991;34:146-52.
28. Sany J, Anaya JM, Canovas F, et al. Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 1993;20:1129-32.
29. Carpenter MT, West SG, Vogelgesang SA, Casey Jones DE. Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Orthopedics 1996;19:207-10.
30. Jain A, Witbreuk M, Ball C, Nanchahal J. Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J Hand Surg [Am] 2002;27:449-55.
31. Murata K, Yasuda T, Ito H, et al. Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod Rheumatol 2006;16:14-9.